Hepatitis Forums

Hepatitis B Main Forums => Hepatitis B => Topic started by: Hep Editors on August 02, 2019, 11:19:53 am

Title: Paper Claiming Viread Bests Baraclude as Hep B Treatment Is Retracted
Post by: Hep Editors on August 02, 2019, 11:19:53 am
Korean scientists have retracted a paper they published last September that found that treating hepatitis B virus (HBV) with Viread (tenofovir disoproxil fumarate) was associated with a lower risk of death or liver transplantation than Baraclude (entecavir), MedPage Today reports. However, research still indicates that hep B treatment with Viread is superior to Baraclude at reducing the risk of hepatocellular carcinoma (HCC, the most common form of liver cancer).

Above all, researchers believe that more investigation—including a thorough meta-analysis of existing data as well as additional observational studies—is needed to sort out what seem to be conflicting signals about which drug is best for treating HBV.